Products with Anti-bone loss bioactivity
| Cat.No. | Product Name |
|---|---|
| BCN2396 | Genistin |
| Supplementation of Genistin alone or with selenium provides antioxidant defense with high-potential chemopreventive activity against DMBA-induced mammary tumors more than selenium alone.Intravitreal injection of Genistin is safe and effective in reducing traumatic PVR in clinical treatment. | |
| BCN2739 | Trachelogenin |
| 1. Trachelogenin has antiproliferative effect, the mechanism is related to affect the phosphorylation of key proteins such as β-Catenin, c-Myc and GSK3 in the β-Catenin signaling pathway in a concentration-dependent manner. | |
| BCN3364 | Alisol B |
| 1. Alisol B can suppress C3a induced epithelial-mesenchymal transition . 2. Alisol B may be a potential novel therapeutic molecule for bone disorders through targeting the differentiation of osteoclasts as well as their functions. 3. Alisol B also inhibited RANKL-induced expression of NFATc1 and c-Fos, which are key transcription factors for osteoclastogenesis. 4. The molecular target of Alisol B is the sarcoplasmic/endoplasmic reticulum Ca(2+) ATPase, it provides detailed insights into the cytotoxic mechanism of a novel antitumor compound. | |
| BCN4557 | Furan-2-carboxylic acid |
| Furan-2-carboxylic acid, an orally active selective human cathepsin K inhibitor, may have the therapeutic potential for the treatment of diseases characterized by excessive bone loss including osteoporosis.Furan-2-carboxylic acid also has anti-bacterial effect, inhibits the proliferation of some slow-growing or difficult-to-culture bacteria on the plates. | |
| BCN4995 | Harpagoside |
| Harpagoside has anti-inflammatory effects, it blocks lipopolysaccharide (LPS)-induced bone loss in an inflammatory osteoporosis model, and it does not prevent ovariectomy-mediated bone erosion in a postmenopausal osteoporosis model, it may lead to a partial prevention of obesity-induced atherosclerosis by attenuating inflammatory responses. Harpagoside suppresses lipopolysaccharide-induced iNOS and COX-2 expression through inhibition of NF-κB activation. Harpagoside exerts neuroprotection effect and ameliorates learning and memory deficit appears to be associated, at least in part, with up-regulation of brain-derived neurotrophic factor (BDNF) content as well as activating its downstream signaling pathways, e.g., MAPK/PI3K pathways. | |
